Phase 1 N=31 A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)
Tumors
Primary: Level of Biomarkers — 24.6; NA; 34.3; 23.0 Percent pCDC2-positive cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=10 Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)
Liver Fibrosis · Hepatitis C Virus
Primary: Repeated Maximum Liver Elastic Stiffness (Kilopascal [kPa]) Measurements — 4.54; 4.64; 5.10; 5.14 kPa
Phase 1 N=36 Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)
Hypertension
Primary: Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT) — 3.44; 3.55 ng/minute — p=0.067
Phase 1 N=160 A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.
Healthy
Primary: Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite. — 39.14; 30.01; 38.85; 29.33 ng/mL
Phase 1 N=10 Study to Evaluate Potential Food Effects
Healthy
Primary: Cmax — 2567.9; 3568.9 ng/mL
Phase 1 N=140 A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
Magnetic Resonance Imaging
Primary: Plasma Clearance Estimates of Gadobutrol by Age Group — 2.07; 3.28; 4.90; 3.24 L/h
Phase 1 N=76 Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Stomach Neoplasms
Primary: Number of Participants With First-cycle Dose Limiting Toxicities (DLTs) — 1; 0; 3; 2 participants
Phase 1 N=71 Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
Leukemia, Myelocytic, Acute Myelodysplastic Syndromes · Myelodysplastic Syndromes
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 participants
Phase 1 N=14 Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 401.655; 360.619 hr*ng/mL
Phase 1 N=158 Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets (P06328)
Healthy Postmenopausal Females
Primary: Maximum Observed Plasma Concentration of NOMAC (Cmax of NOMAC) — 6.22; 4.51; 8.03; 7.20 ng/mL
Phase 1 N=28 SPD544 High Strength Bioequivalence Study
ADHD
Primary: Area Under the Steady-state Plasma Concentration-time Curve (AUC 0-t) for Methylphenidate Hydrochloride (MPH) Using Two Different Formulations (Equasym XL and Metadate…
Phase 1 N=26 Bioequivalence Study Of Diltiazem In 60 Mg Tablets As Tilazem 60® Made by Pfizer, S.A. De C.V., Versus Angiotrofin® 60 Mg Made by Amstrong Laboratorios De Mexico, S.A. De C.V.
Healthy
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] — 463.41; 498.87 ng*hr/mL
Phase 1 N=9 A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Participants Experiencing Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
Diabetes Mellitus Type 2
Primary: Safety and Tolerability of EGT0001474 — 5; 0; 9; 3 Events
Phase 1 N=78 Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers
Safety and Tolerability of EGT0001474 in Healthy Volunteers
Primary: Cmax — 12.7; 28; 90.7; 194 ng/ml